Bank of New York Mellon
GTBP icon

Bank of New York Mellon’s GT Biopharma GTBP Stock Holding History

Bank of New York Mellon’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,175
Closed -$24.3K – 4227
2023
Q4 		$24.3K Hold
3,175
– – ﹤0.01% 4221
2023
Q3 		$23K Hold
3,175
– – ﹤0.01% 4242
2023
Q2 		$29.7K Hold
3,175
– – ﹤0.01% 4243
2023
Q1 		$52.4K Hold
3,175
– – ﹤0.01% 4189
2022
Q4 		$84.4K Hold
3,175
– – ﹤0.01% 4147
2022
Q3 		$167K Sell
3,175
-114
-3% -$8.72K ﹤0.01% 4079
2022
Q2 		$294K Sell
3,289
-1,446
-31% -$110K ﹤0.01% 3890
2022
Q1 		$409K Sell
4,735
-102
-2% -$9K ﹤0.01% 3832
2021
Q4 		$441K Buy
4,837
+265
+6% +$39.7K ﹤0.01% 3882
2021
Q3 		$925K Buy
4,572
+2,615
+134% +$787K ﹤0.01% 3435
2021
Q2 		$910K Buy
+1,957
New +$813K ﹤0.01% 3481

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of New York Mellon's GTBP Position: Q1 2024 in Review

Bank of New York Mellon sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 3,175 shares — an estimated $24.3K sold.

Bank of New York Mellon first reported a position in GTBP in Q2 2021 and held it in 11 quarters. The position peaked at $925K in Q3 2021. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Bank of New York Mellon reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 3,175 GT Biopharma shares in Q1 2024, an estimated $24.3K.
  • Bank of New York Mellon first reported a position in GT Biopharma in Q2 2021 and held it in 11 quarters.
  • Bank of New York Mellon's GT Biopharma position peaked at $925K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.